MK4827 Niraparib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：MK4827 Niraparib	Purity：99% min
CAS NO：1038915-60-4	Solubility：DMSO : ≥ 32 mg/mL (99.88 mM)
Molecular Formula：C₁₉H₂₀N₄O	Package：Package according to customer requirements
Molecular Weight：320.388	Storage：Store at -20℃

Quality control

Remarks

Niraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor that radiosensitizes human lung and breast cancer cells. Niraparib inhibits PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM respectively. Niraparib is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer.

Properties:

Density: 1.34±0.1 g/cm3 (calc.)

Boiling Point: 463.6±45.0 °C (760 mmHg, calc.)

Flash Point: 234.188ºC

PARP Inhibitors Related Products:

Veliparib hcl; Olaparib; XAV-939; Rucaparib; Talazoparib; A-966492; PJ34 HCl; Pamiparib; WIKI4; G007-LK; AZD2461; Saroglitazar; Veliparib

References

[1]. Jones P, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.

[2]. Bridges KA, et al. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5(13):5076-86.